Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.94 |
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SLC13A5 | Q86YT5 | 5/20 | 0.42 |
| ▸ | CPT2 | P23786 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL40883 | 1.00 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372184 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372127 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372377 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372724 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL3792172 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL9662579 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372702 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL11906205 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL372650 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9962628-B2 | Use of citrate solution for affinity chromatographic purification of CRP using phosphocholine and derivatives thereof | PENTRACOR GMBH (DE) | 2018-05-08 | — | — | US | claimed |
| EP-3083665-B1 | USE OF A CITRATE SOLUTION FOR THE AFFINITY-CHROMATOGRAPHIC PURIFICATION OF CRP USING PHOSPHOCHOLIN AND ITS DERIVATIVES | PENTRACOR GMBH (DE) | 2018-01-10 | — | — | EP | claimed |
| US-20170319982-A1 | USE OF A CITRATE SOLUTION FOR AFFINITY CHROMATOGRAPHIC PURIFICATION OF CRP USING PHOSPHOCHOLINE AND DERIVATIVES THEREOF | PENTRACOR GMBH (DE) | 2017-11-09 | — | — | US | claimed |
| WO-2013028574-A2 | AQUEOUS LITHIUM AIR BATTERIES | POLYPLUS BATTERY COMPANY (US) | 2013-02-28 | — | — | WO | claimed |
| US-6855678-B2 | Medical residue treatment composition comprising a lithium salt | WHITELEY CORPORATION PTY LTD (AU) | 2005-02-15 | — | — | US | claimed |
| US-20030161758-A1 | Medical residue treatment composition | WHITELEY CORPORATION PTY LTD (AU) | 2003-08-28 | — | — | US | claimed |
| WO-2002007789-A1 | MEDICAL RESIDUE TREATMENT COMPOSITION | WHITELEY REGINALD KEITH (AU) | 2002-01-31 | — | — | WO | claimed |
| US-12390569-B2 | Simplified regeneration of apheresis columns | PENTRACOR GMBH (DE) | 2025-08-19 | — | — | US | disclosed |
| EP-3762065-B1 | SIMPLIFIED REGENERATION OF APHERESIS COLUMNS | PENTRACOR GMBH (DE) | 2025-04-16 | — | — | EP | disclosed |
| CN-115052677-B | Use of alkali metal hydroxide solutions for regeneration of single-column columns | 彭特科尔有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-114870061-B | Air spray based on virus blocking agent and application thereof | 康码（上海）生物科技有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-118104655-A | Disinfectant based on virus blocking agent and application thereof | 康码（上海）生物科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| WO-2023232096-A1 | AIR SPRAY BASED ON VIRUS BLOCKING AGENT, AND USE THEREOF | 康码（上海）生物科技有限公司 | 2023-12-07 | — | — | WO | disclosed |
| EP-2264109-A1 | Process for preparing surface-reacted calcium carbonate and its use | Omya Development AG (CH) | 2010-12-22 | — | — | EP | disclosed |
| CN-1306009-C | Flame retardant and method for producing same | BIRGER NILSSON JENS (AU) | 2007-03-21 | — | — | CN | disclosed |
| CN-1681905-A | Flame retardant and method for producing same | BIRGER NILSSON JENS (AU) | 2005-10-12 | — | — | CN | disclosed |
| US-6855678-B2 | Medical residue treatment composition comprising a lithium salt | WHITELEY CORPORATION PTY LTD (AU) | 2005-02-15 | — | — | US | disclosed |
| US-20030161758-A1 | Medical residue treatment composition | WHITELEY CORPORATION PTY LTD (AU) | 2003-08-28 | — | — | US | disclosed |
| WO-2002007789-A1 | MEDICAL RESIDUE TREATMENT COMPOSITION | WHITELEY REGINALD KEITH (AU) | 2002-01-31 | — | — | WO | disclosed |
| US-5453472-A | Antideposit agents for polymerization reactor walls | BASF AKTIENGESELLSCHAFT (DE) | 1995-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170319982-A1 | USE OF A CITRATE SOLUTION FOR AFFINITY CHROMATOGRAPHIC PURIFICATION OF CRP USING PHOSPHOCHOLINE AND DERIVATIVES THEREOF | PHOSPHO1, ACP1, ALB | MEN1 4690/4885ALDH1A1 4682/4885HMGCR 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.